Do Biomarkers Explain Excess Mortality in HIV-Positive Individuals?

Increased baseline levels of biomarkers for inflammation, monocyte activation, and coagulation accounted for little of the increased mortality.

Despite the availability of effective antiretroviral therapy, HIV-positive people have excess mortality compared with HIV-negative people. Increased levels of biomarkers for inflammation (interleukin-6), monocyte activation (sCD16), and coagulation (d-dimer) have been associated independently with increased risk for death in both HIV-positive and HIV-negative populations. To assess whether adjusting for baseline levels of these biomarkers alters the increased mortality associated with HIV infection, investigators analyzed data from the Biomarker Cohort of the Veterans Aging Cohort Study (Med Care 2006; 44(8 Suppl 2):S13).

A total of 2350 veterans were followed from the date of blood draw for the biomarker assays until death or July 25, 2013.…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Do Biomarkers Explain Excess Mortality in HIV-Positive Individuals?

Topics

Reviewing Author